Abstract
The clinical efficacy and adverse effects of nandrolone decanoate (Deca-Durabolin) were investigated in a double-blind placebo-controlled multicentre study in female patients with systemic lupus erythematosus (SLE). The patients received 100 mg Deca-Durabolin or placebo once every 2 weeks for 3 months. At the end of the study, 36 patients (18 on placebo and 18 on Deca-Durabolin) were evaluated. Beneficial effects were observed on arthralgia, and/or arthritis and minor vasculitis. Possible beneficial effects were seen on polymyalgia, active SLE rash, oral and/or nasal ulcerations and pleural and pericardial pain in the Deca-Durabolin-treated patients. The overall clinical assessment score showed that Deca-Durabolin would influence the disease course by lowering significantly the disease activity score. However, this treatment is still hampered by adverse reactions such as voice alterations and hirsutism. Therefore, the development of androgen-derived steroids free from androgenic activity should be encouraged, since these compounds may contribute to a new therapeutic modality in female SLE patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
